UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of operative time on complications following primary total hip arthroplasty: analysis of the NSQIP database

Hip international, 2021-03, Vol.31 (2), p.231-236

2021

Volltextzugriff (PDF)

Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management

Urologic oncology, 2024-05, Vol.42 (5), p.144-154

2024

Volltextzugriff (PDF)

A model of spontaneous transformation of rat prostate epithelial cells

The FASEB journal, 2011-04, Vol.25, p.792.1-792.1

2011

Volltextzugriff (PDF)

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

The lancet oncology, 2018-04, Vol.19 (4), p.497-509

2018

Volltextzugriff (PDF)

Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial

JAMA surgery, 2020-03, Vol.155 (3), p.e195410

2020

Volltextzugriff (PDF)

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

NPJ breast cancer, 2021-11, Vol.7 (1), p.142-142, Article 142

2021

Volltextzugriff (PDF)

Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.510-510

2019

Volltextzugriff (PDF)

Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.514-514

2017

Volltextzugriff (PDF)

Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.520-520

2017

Volltextzugriff (PDF)

Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS1149-TPS1149

2014

Volltextzugriff (PDF)

New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461

Genes chromosomes & cancer, 2013-04, Vol.52 (4), p.385-401

2013

Volltextzugriff (PDF)

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

Leukemia, 2011-05, Vol.25 (5), p.800-807

2011

Volltextzugriff (PDF)

Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer

Journal of thoracic oncology, 2009-09, Vol.4 (9), p.1117-1125

2009

Volltextzugriff (PDF)

Criterion Validity of Medicare Chemotherapy Claims in Cancer and Leukemia Group B Breast and Lung Cancer Trial Participants

JNCI : Journal of the National Cancer Institute, 2005-07, Vol.97 (14), p.1080-1083

2005

Volltextzugriff (PDF)

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430

Journal of thoracic oncology, 2008-11, Vol.3 (11), p.1301-1307

2008

Volltextzugriff (PDF)

Fluorescent in situ hybridization for identifying cytogenetic abnormalities in inadequate and suboptimal specimens

Pathobiology (Basel), 1998, Vol.66 (5), p.216-220

1998

Volltextzugriff (PDF)

Fluorescent in situ hybridization for assessing the proportion of cells with trisomy 4 in a patient with acute non-lymphoblastic leukemia

Annals of clinical and laboratory science, 1995-07, Vol.25 (4), p.330-335

1995

Volltextzugriff (PDF)

A Multimodal Approach in the Diagnosis of Patients with Hematopoietic Disorders

Cancer genetics and cytogenetics, 1999-02, Vol.109 (1), p.14-20

1999

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Humans
(15)
Male
(11)
Oncology
(11)
Aged
(9)
Female
(9)
Middle Aged
(9)
Adult
(7)
Aged, 80 And Over
(6)
Chemotherapy
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Biological And Medical Sciences
(5)
Medical Sciences
(5)
Treatment Outcome
(5)
Breast Cancer
(4)
Hematologic And Hematopoietic Diseases
(4)
Karyotyping
(4)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(4)
Prognosis
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of operative time on complications following primary total hip arthroplasty: analysis of the NSQIP database

Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management

A model of spontaneous transformation of rat prostate epithelial cells

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study

Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study

Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess)

inv(16)/t(16;16) acute myeloid leukemia with non–type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations

Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC)

Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC)

New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer

Criterion Validity of Medicare Chemotherapy Claims in Cancer and Leukemia Group B Breast and Lung Cancer Trial Participants

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430

Fluorescent in situ hybridization for identifying cytogenetic abnormalities in inadequate and suboptimal specimens

Fluorescent in situ hybridization for assessing the proportion of cells with trisomy 4 in a patient with acute non-lymphoblastic leukemia

A Multimodal Approach in the Diagnosis of Patients with Hematopoietic Disorders

Suchergebnisse filtern